By Dr. Chinta SidharthanApr 26 2024Reviewed by Lily Ramsey, LLM In a recent study published in the journal JAMA Network Open, researchers investigated whether the coronavirus disease 2019 vaccine for adolescents between the ages of 12 and 15 years, which was approved in May 2021, was associated with changes in the incidence of severe acute respiratory syndrome coronavirus 2 and related hospitalizations among the pediatric population in California, United States .
Since children and adolescents were not found to be at a high risk of severe COVID-19, developing vaccines for the younger populations was of secondary priority during the peak periods of the pandemic. A better understanding of the impact of the vaccine in lowering incidence rates, reducing the severity of the disease, and mitigating the need for hospitalization is essential in formulating future public health policies on booster doses and developing vaccines against emerging SARS-CoV-2 variants.
For the statistical analyses, the researchers grouped the cases based on county of residence, as well as age groups according to vaccine eligibility. The researchers stated that their results among the pediatric population were similar to those from various U.S. and Israeli studies reporting the effectiveness of the COVID-19 vaccine in averting a substantial number of COVID-19 cases among the adult population.
Covid-19 Adolescents Children Coronavirus Pandemic Public Health Respiratory Ribonucleic Acid SARS SARS-Cov-2 Severe Acute Respiratory Severe Acute Respiratory Syndrome Syndrome Vaccine
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: MENnewsdesk - 🏆 23. / 69 Read more »
Source: Netmums - 🏆 42. / 63 Read more »
Source: leedslivenews - 🏆 118. / 51 Read more »
Source: nottslive - 🏆 96. / 52 Read more »
Source: Daily_Record - 🏆 9. / 89 Read more »
Source: medical_xpress - 🏆 101. / 51 Read more »